Implantica's Q3 2026 Report: U.S. Launch of RefluxStop and Growth Highlights

Implantica Reports Q3 2026 Performance and Milestones



Implantica, a pioneering medtech company, has recently published its Interim Report for the first nine months of 2026, highlighting substantial growth and the launch of its innovative product in the U.S. market. The third quarter of 2026 was particularly noteworthy for several reasons, most prominently the granting of the FDA Premarket Approval (PMA) for RefluxStop® on August 20.

Key Achievements in Q3 2026



One of the major milestones achieved was the successful execution of the first RefluxStop procedures by Dr. John Lipham at the University of Southern California (USC) in early November 2026, which marks a significant entry for Implantica into the vast U.S. medical device market. This launch was preceded by a strong reception at the American Foregut Society Annual Meeting, where leading surgeons and gastroenterologists expressed great interest, resulting in over 120 attendees engaging in discussions and meetings regarding the product.

In terms of sales performance, European markets showcased impressive growth, with a 105% year-on-year increase in Q3 sales. This growth can be attributed to the expanding adoption of RefluxStop by hospitals, including notable facilities such as Evangelisches Krankenhaus Wesel in Germany and Hospital Quirónsalud San José in Madrid. The company reported net sales amounting to TEUR 748 for the quarter, reflecting a robust trajectory and increasing demand for innovative treatments.

The company has also significantly strengthened its U.S. organization with the recruitment of experienced personnel, including three Regional Sales Directors, a Surgical Training Lead, and two clinical affairs specialists. This enhancement positions Implantica well for the commercialization of RefluxStop in the United States.

Financial Overview



Financially, Implantica's operating loss in Q3 amounted to TEUR 4,511, slightly higher than the previous year's loss of TEUR 4,432, while the gross margin was stable at an impressive 94%. Despite the challenges, the loss after tax reduced comparatively to TEUR 3,406, indicating a gradual improvement in financial health. For the first nine months of 2026, net sales increased by 51% to TEUR 2,322, further establishing a strong market presence.

Future Developments and Trainings



As we look to the future, Implantica has highlighted plans for ongoing surgeon training programs, vital for effectively integrating RefluxStop into surgical practices across the U.S. The preliminary findings presented during the European Foregut Society meeting in November, showcased superior outcomes of RefluxStop compared to traditional fundoplication procedures, reaffirming the device's transformative potential in treating gastroesophageal reflux disease (GERD).

In sum, the advancement of RefluxStop® into the U.S. market is a historic milestone for Implantica, which not only enhances treatment options for GERD patients but also sets the stage for future growth and innovation in medical technology. With strong clinical outcomes and expanding market presence, Implantica is poised to redefine standards of care for reflux disease and establish itself as a global leader in the medtech sector.

For more detailed insights, stakeholders are invited to join the upcoming teleconference scheduled on November 19, 2026, featuring CEO Peter Forsell and CFO Andreas Öhrnberg, where they will further discuss these developments and the company’s strategic directions moving forward.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.